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Background: Previous studies have relied on international spirometry criteria to diagnose COPD 
in patients with lung cancer without considering the effect lung cancer might have on spirometric 
results. The aim of this study was to examine the prevalence of COPD and emphysema at the 
time of primary lung cancer diagnosis and to examine factors associated with survival.
Materials and methods: Medical records, pulmonary function tests, and computed tomogra-
phy scans were used to determine the presence of COPD and emphysema in patients diagnosed 
with primary lung cancer at the University Hospital of North Norway in 2008–2010.
Results: Among the 174 lung cancer patients, 69% had COPD or emphysema (39% with COPD, 
59% with emphysema; male:female ratio 101:73). Neither COPD nor emphysema were signifi-
cantly associated with lung cancer mortality, whereas patients with non-small-cell lung cancer 
other than adenocarcinoma and squamous cell carcinoma had a risk of lung cancer mortality 
that was more than four times higher than that of patients with small-cell lung cancer (hazard 
ratio [HR] 4.19, 95% confidence interval [CI] 1.56–11.25). Females had a lower risk of lung 
cancer mortality than males (HR 0.63, 95% CI 0.42–0.94), and patients aged $75 years had a 
risk that was twice that of patients aged ,75 years (HR 2.48, 95% CI 1.59–3.87). Low partial 
arterial oxygen pressure (4.0–8.4 kPa) increased the risk of lung cancer mortality (HR 2.26, 
95% CI 1.29–3.96). So did low partial arterial carbon dioxide pressure (3.0–4.9 kPa) among 
stage IV lung cancer patients (HR 2.23, 95% CI 1.29–3.85). Several patients with respiratory 
failure had previously been diagnosed with COPD.
Conclusion: The observed prevalence of COPD was lower than that in previous studies. Neither 
COPD nor emphysema were significantly associated with lung cancer mortality.
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Introduction
Lung cancer is the leading cause of cancer death worldwide, accounting for more 
than a million deaths annually.1,2 A Canadian study using life-table methodology 
found that 172 in 1,000 males and 116 in 1,000 females who currently smoke will 
eventually develop lung cancer, in addition to 13 in 1,000 male and 14 in 1,000 
female nonsmokers.3 Another study reported that 16% of male and 10% of female 
cigarette smokers die of lung cancer.4 Overall 5-year lung cancer survival is poor, at 
approximately 15%.5,6
COPD is characterized by airflow obstruction in the lungs and symptoms related to 
decreased expiratory volume.7 One study reported that about 26% of heavy smokers 
develop clinically significant COPD.8 Another study reported that COPD affects 
15%–20% of smokers and 50%–80% of lung cancer patients with a substantial smoking 
history.9 Indeed, 40%–70% of lung cancer patients also have COPD, and the risk of 
COPD is sixfold higher in lung cancer patients than in matched smokers, leading to the 
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conclusion that COPD and lung cancer must share risk fac-
tors other than tobacco exposure.10–14 Such factors as airflow 
limitation, smoking, and genotype can predispose a person to 
COPD and lung cancer,10 and smokers have a host suscepti-
bility to both these diseases.4,8,9,15 However, the association 
between COPD and lung cancer is largely explained by smok-
ing habits and the timing of COPD diagnosis. Powell et al 
reported that 23% of lung cancer cases had a prior diagnosis 
of COPD, compared with only 6% of controls.16
Pulmonary emphysema is defined morphologically as the 
enlargement of air spaces distal to the terminal bronchiole, 
due to dilatation or destruction of alveolar walls.7,17 Computed 
tomography (CT)-detected emphysema has been shown to 
be associated with an increased risk of lung cancer,15,18–20 and 
even nonsmokers with emphysema have an elevated risk of 
lung cancer.12,13
Inflammatory processes may also play a central role 
in carcinogenesis,11 and COPD and emphysema are major 
causes of inflammation in lung tissue.12 However, precise 
details of the relationship between COPD, emphysema, and 
lung cancer remain uncertain. Whether airflow obstruction 
predisposes to lung cancer or whether both arise from a com-
mon factor is unclear and beyond the scope of this study.6
Previous studies either relied on international spiro-
metry criteria to diagnose COPD in patients with lung cancer 
without considering the effect lung cancer might have on 
the spirometric results or used variable spirometric criteria 
for pulmonary function testing (PFT) that did not conform 
to revised standard guidelines. The aim of this study was 
to examine the prevalence of COPD and emphysema at the 
time of primary lung cancer diagnosis using a combination 
of medical records, PFT (including spirometry and blood 
gases), and CT scans of the lungs. We also examined factors 
associated with lung cancer mortality.
Materials and methods
Data
We retrospectively reviewed the medical records of the 
174 patients (101 males and 73 females between 31 and 
90 years of age) diagnosed with primary lung cancer from 
2008 to 2010 at the University Hospital of North Norway. 
Information on age, sex, smoking status, body mass index 
(BMI), lung cancer diagnosis, histologic type, tumor size, 
and cancer stage was taken from medical records, as were 
PFT results like spirometry (forced vital capacity [FVC] 
and forced expiratory volume in 1 second [FEV
1
]), arterial 





and carboxyhemoglobin [COHb] in arterial blood plasma), 
and CT scans of the lungs. Smoking status was recorded as 
only two categories: nonsmoker and smoker/ex-smoker. An 
anonymized version of the data set is available in Table S1. 
The study was approved by the Regional Committee of 
Research Ethics of North Norway. Patient consent was not 
obtained as this is a retrospective study.
lung cancer
Histologic lung cancer was categorized as small-cell lung 
cancer (SCLC) and non-SCLC (NSCLC). NSCLC was 
then further categorized as adenocarcinoma, squamous cell 
carcinoma (SCC), or other, which consisted primarily of 
large-cell carcinoma and undifferentiated carcinoma of the 
lungs. Patients with bronchial carcinoids were excluded. 
Cancer stage was recorded using the TNM classification and 
the staging I–IV.21–24
assessment of COPD
Spirometry values at lung cancer diagnosis (Jaeger Master-
Screen PFT; BD, Franklin Lakes, NJ, USA) were recorded 
using European reference values. FVC and FEV
1
 were 
recorded in medical records in liters and percentage pre-
dicted values, as well as FEV
1
/FVC%. The GOLD (Global 
initiative for chronic Obstructive Lung Disease) criteria were 





/FVC%:7 patients with an FEV
1
/FVC 
ratio #70% were classified as having COPD in all grades; 
grade 1 was defined as having an FEV
1
 $80%; grade 2 as 
50% # FEV
1
 , 80%; grade 3 as 30% # FEV
1
 , 50%; and 
grade 4 as FEV
1
 ,30%.
Patients were classified as having COPD at lung cancer 
diagnosis if they had a previous spirometric diagnosis of 
COPD in their medical records (known COPD), or if they 
fulfilled the spirometric criteria, including the authentic flow-
volume curve seen in obstructive lung disease (undiagnosed 
COPD). Patients with bronchial asthma and a normal PFT 
shortly before lung cancer diagnosis were classified as not 
having COPD (no COPD), as were patients with an obvious 
explanation for their spirometric findings, such as a central 
tumor or atelectasis. Patients with missing data were catego-
rized as “missing – spirometry”.
assessment of emphysema
The presence of emphysema at lung cancer diagnosis was 
determined based on information from CT scans (Sensation 
16; Siemens AG, Munich, Germany) contained in medical 
records. All CT scans were reviewed at diagnosis by one 
radiologist and two pulmonologists, using previously 




COPD in primary lung cancer
published methods. When emphysema was detected visually 
in the CT scan (ie, with a score $1), the patient was classified 
as having emphysema.15,25,26
statistical analysis
Survival times were recorded in days from diagnosis of 
lung cancer, and were analyzed using the Cox proportional 
hazard model. Each patient was followed from the date of 
lung cancer diagnosis until death from primary lung cancer 
or the end of the study period (October 1, 2014), whichever 
came first. The following variables were also recorded at 
diagnosis and considered time-independent covariates in the 
Cox model: age, sex, smoking status, BMI, histologic type, 




, COHb, and 
emphysema.
Preliminary analyses were performed on subsets of the 
data, in order to identify possible interactions between cova-
riates. The only significant interaction was between cancer 
stage and PaCO
2
. As part of the preliminary analyses, we 
categorized age into four groups: 31–64, 65–69, 70–74, and 
75–90 years. The three youngest age-groups were found 
to have an equal effect on lung cancer mortality, and age 
was thus reduced to a dichotomous variable (31–74 and 
75–90 years). PaO
2
 was divided into three categories (4–8.4, 
8.5–9.9, and $10 kPa), as was PaCO
2
 (3–4.9, 5–5.9, and 
6–10 kPa).
It is common to include cancer stage as a categorical 
covariate in a Cox proportional hazard regression model, 
but this must be done with care, because a mixture of 
individuals with cancer stages ranging from I to IV may 
give rise to nonproportionality in hazard ratios (HRs). This 
phenomenon is thoroughly discussed in the literature.27 
We tested proportionality, and did not find any significant 
violations of the proportional hazard assumption. Another 
possible feature of the covariate cancer stage is heterogene-
ity within each stage, where some individuals have a more 
seriously developed cancer than others within the same stage. 
Such heterogeneity can be modeled as a frailty covariate.27 
We considered this in the preliminary analyses, and found 
only minor changes in the coefficient estimates compared to 
a model without frailty.
In addition to the traditional Cox model, we modeled the 
data as a randomized Wiener process27 to identify whether 
a covariate was of one of two types: 1) a measure of how 
far the cancer had advanced; or 2) a causal influence on the 
development of the disease.
Results are reported as HRs with 95% confidence 
intervals (CIs), and P-values are given. Calculations 
were performed in the statistical computing language R28 
using the R package Survival.29 A test for violation of the 
proportional hazard assumption in the Cox model was 
performed with the R-routine cox.zph29 in the Survival 
package. For the Wiener process, we used the R package 
“invGauss”.30
Results
Of the 174 patients, 120 (69%) had COPD and/or emphysema 
(67 [38.5%] with COPD and 102 [58.6%] with emphysema). 
Of the 67 patients with COPD, only 18 (26.9%) did not have 
coexisting emphysema. The male:female ratios were 101 
(58%):73 (42%) for all patients, 40 (59.7%):27 (40.3%) 
for patients with COPD, and 65 (63.7%):37 (36.3%) for 
patients with emphysema (Table 1). Of all the patients, 138 
(80%) had stage III–IV lung cancer at the time of diagnosis. 
Only eight (23%) of the 35 patients with stage I–II lung 
cancer had neither COPD nor emphysema (Table 1). Of the 
18 patients with COPD without concomitant emphysema, 
all but two had stage III–IV lung cancer (data not shown). 
Only five patients were nonsmokers, and two had missing 
data on smoking status (data not shown).
Six patients had missing histologic type, and were 
excluded from the analyses. Of the remaining 168 patients, 
27% were diagnosed with SCLC, 37% with adenocarcinoma, 
32% with SCC, and 4% with other – NSCLC (Figure 1). 
We further excluded 23 patients with missing data on at 
least one of the significant factors for lung cancer mortality: 





 values. Finally, we excluded one male 
patient with missing PFT who had a strong influence on the 
Cox-model estimates. Therefore, the final analyses included 
144 patients.
Smoking status, BMI, tumor size, COHb, and emphysema 
were not significant covariates in the Cox model. The risk 
of lung cancer mortality was not significantly different for 
known-COPD/undiagnosed-COPD patients compared to 
no-COPD patients, and missing-spirometry patients had 
a significantly higher risk of lung cancer mortality (HR 
6.33, 95% CI 2.69–14.93). The randomized Wiener process 
identified missing-spirometry patients as a group with more 
advanced cancer. In a separate analysis, we also categorized 
COPD into the four GOLD grades,7 but found no significant 
differences in survival between these grades of COPD (data 
not shown).
Among the histologic types, other – NSCLC patients had 
a risk of lung cancer mortality that was four times higher 
than that of SCLC patients (HR 4.19, 95% CI 1.56–11.25). 





Table 1 Baseline characteristics, means, and standard deviation of lung cancer patients diagnosed at the University hospital of north 
norway in 2008–2010 (n=174) according to presence of COPD and emphysema




n 174 67 53 54
% male 58 59.7 66 48.1
n, cancer stage I + II 35 16 11 8
n, cancer stage III + IV 138 51 42 45
Mean SD Mean SD Mean SD Mean SD
age (years), n=174 67.92 10.17 70.73 8.52 67.58 9.47 64.76 11.80
BMI (kg/m2), n=155 24.97 5.01 25.31 5.23 23.35 4.47 25.93 4.92
FVC (l), n=144 2.62 0.84 2.40 0.75 2.74 0.94 2.81 0.81
FVC (%) predicted 78.70 20.21 73.38 17.29 80.56 22.52 84.43 20.40
FeV1 (l), n=144 1.83 0.67 1.48 0.50 1.99 0.65 2.18 0.67
FeV1 (%) predicted 69.05 21.08 57.50 16.75 74.59 20.87 80.41 18.77
FeV1/FVC (%), n=144 70.17 12.68 62.46 12.05 73.85 11.15 77.61 8.29
PaO2 (kPa, air), n=151 9.93 1.58 9.56 1.34 9.70 1.56 10.65 1.68
PaCO2 (kPa, air), n=151 5.10 0.68 5.22 0.57 5.14 0.86 4.89 0.62
COhb (%), n=144 1.49 1.12 1.40 0.82 1.68 1.40 1.44 1.21
Tumor size (cm)
all patients, n=167 5.13 2.46 5.32 2.55 5.27 2.69 4.73 2.04
Females, n=68 4.73 2.26 4.84 2.16 4.64 2.68 4.67 2.12
Abbreviations: BMI, body mass index; FVC, forced vital capacity; FeV1, forced expiratory volume in 1 second; PaO2, partial arterial oxygen pressure; COhb, carboxyhemoglobin 
(in arterial blood plasma); PaCO2, partial arterial carbon dioxide pressure.
Figure 1 Prevalence of COPD and emphysema by histologic type of primary lung cancer (n=168).
Abbreviations: nsClC, non-small-cell lung cancer; sCC, squamous cell carcinoma; sClC, small-cell lung cancer.
The Wiener process identified other – NSCLC as having 
poorer survival, meaning a more advanced cancer. The risk 
of lung cancer mortality among patients with adenocarcinoma 
and SCC was not significantly different from that of SCLC 
patients (Table 2).
We found a weak but significant effect of sex on lung 
cancer mortality, with females showing a lower risk than 
males (HR 0.63, 95% CI 0.42–0.94). In contrast, advanced 
age was found to increase the risk of lung cancer mortality 
(Table 2). Further results from the Cox model showed that 
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patients with a low PaO
2
 (4.0–8.4), compared to those with 
a high PaO
2
 ($10), had an HR of 2.26 (95% CI 1.29–3.96). 
Among the 28 patients with low PaO
2
, 16 were known-
COPD patients, while only five were no-COPD patients 
(data not shown). Among patients with stage IV lung cancer, 
having a low PaCO
2
 (3.0–4.9) increased the risk of lung 
cancer mortality (HR 2.23, 95% CI 1.29–3.85). Among 
the 33 patients with stage IV lung cancer and a low PaCO
2
, 
there were 19 no-COPD patients and seven known-COPD 
patients (data not shown). The Wiener process showed 
that the effect of having stage IV lung cancer and a low 
PaCO
2
 was due to the presence of advanced cancer at time 
of diagnosis.
Among patients below 75 years of age, 5-year survival with 
stage I lung cancer was 80% in females and 70% in males. Two-
year survival with stage III lung cancer was 60% in females and 
45% in males (Figure 2). Patients (except those with other – 
NSCLC) with missing spirometry showed the poorest 2-year 
survival with stage III lung cancer, at 6% or less, whereas 2-year 
survival among all other patients was 60% and 45% for young 
females and males, respectively, and 28% and 14% in females 
and males aged 75 years and older (Figure 3).
Table 2 Impact of evaluated variables on survival of patients with primary lung cancer according to Cox regression analysis (n=144)
Variables Category HR 95% CI P-value
age (reference ,75 years) $75 years 2.48 1.59–3.87 0.0001
sex Female 0.63 0.42–0.94 0.0239
COPD (reference no – COPD) Known – COPD 1.02 0.65–1.60 0.9388
Undiagnosed – COPD 1.02 0.47–2.23 0.9609
Missing – spirometry 6.33 2.69–14.93 ,0.0001
Histologic type (reference SCLC) adenocarcinoma – nsClC 1.30 0.78–2.15 0.3157
sCC – nsClC 0.99 0.57–1.71 0.9679
Other – nsClC 4.19 1.56–11.25 0.0045
PaO2 (kPa, air), reference $10 4.0–8.4 2.26 1.29–3.96 0.0045
8.5–9.9 1.44 0.91–2.28 0.1172
PaCO2 (kPa, air), reference 5.0–5.9
stage I 3–4.9 1.69 0.31–9.34 0.5456
6–10 11.24 2.64–47.85 0.0011
stage II 3–4.9 1.70 0.47–6.21 0.4226
6–10 19.97 1.92–208.06 0.0123
stage III 3–4.9 1.58 0.77–3.22 0.2096
6–10 0.76 0.22–2.64 0.6644
stage IV 3–4.9 2.23 1.29–3.85 0.0040
6–10 0.28 0.07–1.06 0.0611
Note: Patients with missing data were categorized as “missing – spirometry”.
Abbreviations: HR, hazard ratio; CI, confidence interval; NSCLC, non-small-cell lung cancer; SCC, squamous cell carcinoma; PaO2, partial arterial oxygen pressure; sClC, 
small-cell lung cancer; PaCO2, partial arterial carbon dioxide pressure.
Figure 2 survival curves for primary lung cancer (except other – nsClC) by stage among males and females younger than 75 years.
Note: PaO2 fixed at $10, PaCO2 at 5.0–5.9 kPa.
Abbreviations: nsClC, non-small-cell lung cancer; PaO2, partial arterial oxygen pressure; PaCO2, partial arterial carbon dioxide pressure.






About 80% of patients with primary lung cancer are diag-
nosed with stage III–IV cancer,1,2,5 which is consistent with 
our findings. However, whereas previous studies used history 
of sputum production and spirometry as diagnostic criteria 
for COPD,7,17,18,31 we chose to classify patients as having 
COPD if a diagnosis was present in their medical records, or 
if they had spirometric results, arterial blood-gas results, and 
visual detection of emphysema in their CT scan that indicated 
COPD. Patients with a central tumor with or without coexist-
ing atelectasis as the only known cause of decreased FEV
1
 
were categorized as not having COPD, thus reducing the 
possibility of overdiagnosis of COPD. We found a prevalence 
of COPD of 39%, which is one of the lowest published so 
far.12,15,19,32 The prevalence of emphysema that we observed 
was similar to that in previous studies.15,19 In our study, all 
but two patients with COPD and no concomitant emphysema 
had stage III–IV lung cancer. However, it is important to 
note that emphysema may be less visible on the CT scans 
of patients with advanced lung cancer. Moreover, the PFT 
of patients with lung cancer may be lower, which can mask 
COPD or lead to misdiagnosis.15
This retrospective, descriptive study of patients with 
primary lung cancer included a 5-year survival study. We 
found that lung cancer patients with missing spirometry data 
had the poorest survival. Indeed, many of these patients had 
stage III–IV lung cancer and were too ill to perform PFT at 
time of diagnosis. However, we did not find any significant 
difference in survival between patients with and without 
COPD. The majority of our lung cancer patients with both 
COPD and emphysema had moderate COPD, and due to the 
short survival time of lung cancer patients with advanced-
stage disease, neither COPD nor emphysema had a significant 
impact on survival in this study.
Other-NSCLC patients had poorer survival than 
those with adenocarcinoma, SCC, and SCLC, which is in 
agreement with previous knowledge, as the other histologic 
types of NSCLC have increased malignancy and a lower 
treatment effect.1,2,5 Survival was age-independent until 
75 years of age, and we found weak significantly better sur-
vival in females compared to males. Lung cancer accounts for 
25% of all cancer deaths among females, and this percentage 
continues to increase, possibly due to a lower decrease in 
smoking frequency among females.31 In contrast, lung cancer 
mortality is decreasing in males, although previous studies 
have shown that males generally smoke more pack-years 
than females.31
Respiratory failure affects the prognosis of COPD sur-
vival severely. The information on arterial blood gases in our 
study showed that lung cancer patients with severe hypox-
emia had significantly poorer survival. Moreover, a majority 
of these patients had COPD. Hypercapnia predicted signifi-
cantly poorer survival in patients with stage I lung cancer, 
but there were few patients in this group. A low PaCO
2
 
level indicates hyperventilation provoked by the sensation 
of dyspnea caused by the severity of the lung cancer itself, 
and predicted poorer survival in patients with stage IV lung 
cancer in our study.
This study represents a time period immediately before 
2011, when the Lean method was implemented as a clinical 
Figure 3 survival curve for primary lung cancer (except other – nsClC) stage III by age, sex, and spirometry.
Notes: PaO2 fixed at $10, PaCO2 at 5.0–5.9 kPa. Patients with missing data were categorized as “missing – spirometry”.
Abbreviations: nsClC, non-small-cell lung cancer; PaO2, partial arterial oxygen pressure; PaCO2, partial arterial carbon dioxide pressure.
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pathway facilitator in patients with lung cancer. After the 
introduction of the Lean method, the workup time for lung 
cancer patients decreased from a mean of 64 days to 16 days, 
and the median time from diagnosis to surgery went from 
26.5 days to 15 days,33 both of which could lead to increased 
survival rates.
A previous study showed that there is an association 
between COPD and lung cancer, and that the combination of 
these two diseases leads to a worse outcome. It is reported that 
there are fewer thoracic surgeries performed in patients with 
COPD than in those without, and that PFT, cancer stage, and 
age at diagnosis are associated with the decision to go forward 
with surgery. Older lung cancer patients with COPD can be 
treated with chemotherapy and/or radiation therapy, but a 
systematic, comprehensive assessment of COPD at time of 
bronchoscopy allows us to implement the optimum manage-
ment for lung cancer patients.34,35 For example, patients with 
primary, stage I lung cancer who are ineligible for surgery 
due to COPD are now treated by stereotactic radiation therapy 
with curative intention, and thus achieve improved survival.36 
EGFR-targeted therapy may also increase survival in some 
lung cancer patients with COPD.37
Coexistence of lung cancer and emphysema can be 
assessed by a CT scan. Indeed, low-dose CT scans of the chest 
as screening for lung cancer have reduced the number of lung 
cancer deaths significantly, but costs have to be reduced.25,37 
Preventive interventions should focus on smoking cessation 
and screening for early diagnosis.4,37,38 Future screening 
programs should focus on those 60–74 years of age, smokers, 
identifying patients with COPD, and early detection of lung 
cancer based on low-dose CT scans of the chest.37
Conclusion
The observed prevalence of COPD was lower than that 
in previous studies. Neither COPD nor emphysema were 
significantly associated with lung cancer mortality. However, 
at an early lung cancer stage, diagnosis and grading of COPD 
may have the potential to improve treatment decision and 
prognosis.
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COPD in primary lung cancer
Table S1 survival of primary lung cancer of all 174 patients diagnosed at University hospital of north norway 2008–2010
ID Sex Age-group,  
years




Cancer Stage Time D
1 F 30–74 no COPD 0 10–15 3–4.9 ad-nsClC III 377 1
2 M 30–74 Missing – spirometry 0 na na sCC – nsClC IV 340 1
3 M 30–74 no COPD 1 10–15 3–4.9 sClC IV 157 1
4 M 30–74 no COPD 0 10–15 3–4.9 sClC IV 547 1
5 M 30–74 no COPD 0 10–15 5–5.9 ad-nsClC IV 2,067 1
6 M 30–74 no COPD 0 10–15 5–5.9 sCC – nsClC III 1,243 1
7 M 30–74 no COPD 0 10–15 3–4.9 sCC – nsClC III 279 1
8 M 30–74 Known COPD 1 4–8.4 5–5.9 sClC III 365 1
9 F 75–91 Known COPD 0 10–15 5–5.9 sClC III 620 1
10 M 75–91 Known COPD 0 8.5–9.9 3–4.9 sClC IV 16 1
11 F 30–74 no COPD 0 10–15 3–4.9 Other – nsClC I 803 1
12 M 75–91 no COPD 1 4–8.4 5–5.9 sClC IV 77 1
13 F 30–74 no COPD 0 10–15 5–5.9 ad-nsClC I 353 1
14 M 30–74 no COPD 1 10–15 3–4.9 sClC IV 188 1
15 M 30–74 no COPD 0 10–15 5–5.9 sCC – nsClC II 289 1
16 F 30–74 no COPD 1 4–8.4 6–10 sCC – nsClC III 2,175 1
17 M 30–74 Missing – spirometry 0 10–15 5–5.9 sCC – nsClC IV 104 1
18 M 75–91 Missing – spirometry 1 4–8.4 3–4.9 na IV 10 1
19 M 30–74 no COPD 0 10–15 3–4.9 Other – nsClC IV 41 1
20 M 30–74 no COPD 0 10–15 3–4.9 sClC na 155 1
21 F 30–74 no COPD 0 8.5–9.9 5–5.9 ad-nsClC IV 245 1
22 M 30–74 no COPD 0 10–15 5–5.9 sCC – nsClC IV 116 1
23 F 30–74 no COPD 1 10–15 3–4.9 ad-nsClC IV 131 1
24 M 30–74 Known COPD 1 4–8.4 3–4.9 ad-nsClC IV 287 1
25 M 75–91 no COPD 1 10–15 5–5.9 sCC – nsClC IV 45 1
26 F 30–74 no COPD 0 10–15 3–4.9 ad-nsClC III 1,787 1
27 M 75–91 Undiagnosed COPD 1 8.5–9.9 5–5.9 sCC – nsClC IV 52 1
28 F 30–74 Missing – spirometry 1 4–8.4 5–5.9 sCC – nsClC IV 54 1
29 M 30–74 no COPD 0 10–15 3–4.9 na IV 162 1
30 M 75–91 Known COPD 1 4–8.4 6–10 sCC – nsClC IV 319 1
31 F 30–74 no COPD 0 10–15 3–4.9 ad-nsClC IV 561 1
32 M 30–74 Known COPD 1 4–8.4 5–5.9 sClC IV 1,076 1
33 M 30–74 Missing – spirometry 1 na na sCC – nsClC III 91 1
34 M 75–91 Known COPD 0 10–15 5–5.9 sClC III 27 1
35 M 75–91 no COPD 0 10–15 3–4.9 sClC IV 7 1
36 F 30–74 no COPD 0 4–8.4 5–5.9 ad-nsClC IV 76 1
37 F 75–91 no COPD 0 10–15 3–4.9 ad-nsClC II 192 1
38 F 75–91 no COPD 1 10–15 3–4.9 sCC – nsClC II 370 1
39 F 30–74 no COPD 1 8.5–9.9 6–10 ad-nsClC I 377 1
40 M 75–91 Missing – spirometry 0 10–15 5–5.9 sCC – nsClC IV 36 1
41 F 30–74 Known COPD 0 10–15 5–5.9 Other – nsClC III 33 1
42 M 30–74 Known COPD 0 4–8.4 5–5.9 sClC III 1,461 1
43 M 30–74 no COPD 1 10–15 3–4.9 Other – nsClC IV 141 1
44 F 30–74 Missing – spirometry 1 na na sCC – nsClC III 28 1
45 F 30–74 no COPD 0 8.5–9.9 5–5.9 ad-nsClC IV 576 1
46 F 30–74 Missing – spirometry 1 4–8.4 5–5.9 sClC IV 130 1
47 M 30–74 Known COPD 1 4–8.4 5–5.9 ad-nsClC III 38 1
48 F 75–91 no COPD 1 10–15 3–4.9 ad-nsClC IV 44 1
49 M 30–74 no COPD 1 10–15 5–5.9 ad-nsClC I 2,298 0
50 M 30–74 no COPD 0 10–15 6–10 ad-nsClC III 132 1
51 M 30–74 Undiagnosed COPD 1 8.5–9.9 5–5.9 ad-nsClC III 83 1
52 M 30–74 no COPD 1 10–15 3–4.9 ad-nsClC III 204 1
53 M 30–74 no COPD 1 8.5–9.9 5–5.9 sClC IV 166 1
54 F 75–91 Undiagnosed COPD 0 8.5–9.9 6–10 sCC – nsClC II 50 1
55 F 30–74 no COPD 0 10–15 5–5.9 sClC IV 175 1
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ID Sex Age-group,  
years




Cancer Stage Time D
56 M 75–91 no COPD 1 8.5–9.9 3–4.9 sCC – nsClC III 28 1
57 M 30–74 Undiagnosed COPD 1 10–15 5–5.9 sCC – nsClC I 2,155 1
58 M 30–74 Known COPD 0 10–15 3–4.9 Other – nsClC IV 168 1
59 F 30–74 Missing – spirometry 0 4–8.4 3–4.9 ad-nsClC IV 2 1
60 M 75–91 Known COPD 0 10–15 5–5.9 sCC – nsClC III 415 1
61 M 30–74 no COPD 0 10–15 5–5.9 ad-nsClC IV 917 1
62 M 30–74 Known COPD 1 10–15 5–5.9 sCC – nsClC III 475 1
63 F 30–74 no COPD 0 8.5–9.9 5–5.9 sClC IV 1,485 1
64 M 30–74 Known COPD 1 4–8.4 3–4.9 sClC III 13 1
65 M 75–91 Undiagnosed COPD 1 8.5–9.9 3–4.9 sCC – nsClC III 460 1
66 F 30–74 no COPD 0 na na ad-nsClC III 698 1
67 M 30–74 Known COPD 1 4–8.4 5–5.9 ad-nsClC IV 226 1
68 M 30–74 no COPD 0 8.5–9.9 5–5.9 ad-nsClC IV 184 1
69 F 30–74 no COPD 1 10–15 5–5.9 ad-nsClC I 2,196 0
70 F 30–74 no COPD 0 10–15 5–5.9 ad-nsClC III 265 1
71 F 30–74 no COPD 1 8.5–9.9 3–4.9 sCC – nsClC II 2,189 0
72 M 30–74 no COPD 1 10–15 3–4.9 sCC – nsClC III 287 1
73 M 30–74 Known COPD 1 8.5–9.9 5–5.9 sClC IV 492 1
74 M 30–74 Missing – spirometry 0 8.5–9.9 6–10 sCC – nsClC IV 501 1
75 F 30–74 no COPD 0 8.5–9.9 5–5.9 ad-nsClC II 1,758 1
76 M 30–74 no COPD 0 10–15 5–5.9 sCC – nsClC III 432 1
77 F 30–74 no COPD 0 10–15 5–5.9 sClC III 2,142 0
78 M 30–74 no COPD 1 na na sCC – nsClC II 2,141 0
79 M 30–74 no COPD 1 8.5–9.9 3–4.9 sClC IV 18 1
80 F 30–74 Missing – spirometry 0 10–15 3–4.9 sClC IV 19 1
81 M 75–91 Missing – spirometry 0 na na sClC IV 35 1
82 F 30–74 Missing – spirometry 0 8.5–9.9 3–4.9 sCC – nsClC IV 135 1
83 F 30–74 Known COPD 1 4–8.4 3–4.9 sClC IV 111 1
84 F 30–74 Known COPD 0 na na sClC IV 58 1
85 F 30–74 Undiagnosed COPD 1 10–15 5–5.9 sCC – nsClC III 2,114 0
86 F 30–74 no COPD 0 na na ad-nsClC III 254 1
87 M 75–91 Missing – spirometry 1 na na sClC IV 35 1
88 F 75–91 no COPD 0 4–8.4 3–4.9 ad-nsClC IV 18 1
89 M 75–91 Known COPD 1 10–15 3–4.9 sClC II 417 1
90 M 30–74 Known COPD 1 10–15 5–5.9 ad-nsClC I 249 1
91 F 30–74 Known COPD 1 4–8.4 6–10 ad-nsClC III 630 1
92 F 30–74 Undiagnosed COPD 0 10–15 3–4.9 ad-nsClC IV 22 1
93 M 30–74 no COPD 1 10–15 5–5.9 ad-nsClC III 728 1
94 M 75–91 no COPD 1 8.5–9.9 3–4.9 na III 171 1
95 F 30–74 Known COPD 0 8.5–9.9 5–5.9 sClC IV 512 1
96 F 30–74 Missing – spirometry 1 na na ad-nsClC IV 455 1
97 M 30–74 Known COPD 0 10–15 5–5.9 sClC III 441 1
98 F 75–91 Known COPD 1 4–8.4 5–5.9 sCC – nsClC I 1,329 1
99 M 75–91 Known COPD 1 4–8.4 3–4.9 sCC – nsClC III 163 1
100 F 30–74 no COPD 0 10–15 3–4.9 sClC I 1,902 0
101 F 75–91 no COPD 0 10–15 3–4.9 ad-nsClC IV 537 1
102 F 75–91 no COPD 0 8.5–9.9 5–5.9 na IV 345 1
103 F 75–91 Undiagnosed COPD 0 4–8.4 5–5.9 ad-nsClC IV 159 1
104 M 75–91 Missing – spirometry 0 na na na IV 14 1
105 M 30–74 no COPD 0 8.5–9.9 5–5.9 sClC I 1,983 0
106 M 75–91 Known COPD 1 8.5–9.9 5–5.9 sCC – nsClC II 526 1
107 M 30–74 Missing – spirometry 1 na na ad-nsClC IV 222 1
108 F 75–91 Known COPD 1 na na ad-nsClC IV 82 1
109 M 75–91 Known COPD 0 8.5–9.9 5–5.9 ad-nsClC IV 168 1
110 F 75–91 Known COPD 1 4–8.4 5–5.9 sCC – nsClC III 197 1
111 M 30–74 no COPD 0 na na ad-nsClC IV 1,412 1
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Table S1 (Continued)
ID Sex Age-group,  
years




Cancer Stage Time D
112 F 30–74 no COPD 0 10–15 5–5.9 sCC – nsClC IV 1,092 1
113 M 75–91 no COPD 1 8.5–9.9 3–4.9 sCC – nsClC II 195 1
114 M 30–74 Known COPD 1 10–15 5–5.9 sClC IV 990 1
115 F 75–91 no COPD 1 10–15 5–5.9 ad-nsClC I 1,254 1
116 M 30–74 no COPD 1 8.5–9.9 3–4.9 sCC – nsClC III 789 1
117 F 30–74 Undiagnosed COPD 1 10–15 5–5.9 ad-nsClC II 1,892 0
118 F 75–91 Known COPD 1 8.5–9.9 3–4.9 sClC I 921 1
119 F 30–74 Known COPD 1 4–8.4 5–5.9 sCC – nsClC III 618 1
120 M 30–74 Undiagnosed COPD 0 10–15 5–5.9 sClC I 1,875 0
121 F 30–74 Known COPD 1 8.5–9.9 3–4.9 sCC – nsClC III 69 1
122 M 30–74 Undiagnosed COPD 1 4–8.4 3–4.9 ad-nsClC IV 16 1
123 F 30–74 no COPD 1 10–15 3–4.9 ad-nsClC IV 181 1
124 M 75–91 Known COPD 1 10–15 3–4.9 sCC – nsClC IV 81 1
125 M 30–74 Known COPD 1 10–15 3–4.9 ad-nsClC III 195 1
126 M 30–74 no COPD 1 10–15 3–4.9 sCC – nsClC III 471 1
127 F 30–74 Known COPD 1 8.5–9.9 6–10 sCC – nsClC III 92 1
128 M 30–74 no COPD 1 8.5–9.9 3–4.9 sClC IV 3 1
129 M 30–74 no COPD 1 8.5–9.9 5–5.9 sCC – nsClC IV 153 1
130 M 30–74 Known COPD 1 10–15 6–10 sCC – nsClC I 555 1
131 M 30–74 Known COPD 1 10–15 3–4.9 ad-nsClC III 148 1
132 M 75–91 no COPD 1 na na ad-nsClC I 1,847 0
133 M 30–74 Known COPD 1 10–15 5–5.9 sCC – nsClC III 417 1
134 M 30–74 no COPD 1 10–15 5–5.9 sCC – nsClC I 1,840 0
135 M 30–74 no COPD 1 10–15 5–5.9 sCC – nsClC II 1,875 0
136 F 30–74 no COPD 1 na na ad-nsClC III 776 1
137 M 30–74 no COPD 1 4–8.4 3–4.9 ad-nsClC IV 14 1
138 F 30–74 Undiagnosed COPD 1 10–15 3–4.9 sClC IV 437 1
139 F 30–74 Known COPD 1 10–15 3–4.9 ad-nsClC III 1,818 0
140 M 75–91 no COPD 1 8.5–9.9 5–5.9 sClC III 924 1
141 M 75–91 Known COPD 1 10–15 5–5.9 sCC – nsClC I 1,797 0
142 M 30–74 Known COPD 0 8.5–9.9 3–4.9 sCC – nsClC IV 214 1
143 F 30–74 Known COPD 1 8.5–9.9 5–5.9 sCC – nsClC I 1,744 0
144 M 75–91 Missing – spirometry 1 8.5–9.9 5–5.9 sCC – nsClC III 701 1
145 M 30–74 no COPD 0 10–15 3–4.9 ad-nsClC IV 278 1
146 M 75–91 Known COPD 1 10–15 3–4.9 ad-nsClC IV 397 1
147 M 30–74 no COPD 1 10–15 5–5.9 sClC III 176 1
148 M 30–74 Missing – spirometry 1 4–8.4 5–5.9 ad-nsClC IV 37 1
149 M 30–74 Known COPD 0 10–15 5–5.9 ad-nsClC IV 290 1
150 F 30–74 Known COPD 1 8.5–9.9 5–5.9 na III 249 1
151 M 30–74 Missing – spirometry 1 na na ad-nsClC IV 131 1
152 F 30–74 no COPD 1 na na sClC IV 288 1
153 M 75–91 Known COPD 1 10–15 6–10 sCC – nsClC I 98 1
154 F 30–74 no COPD 0 10–15 5–5.9 ad-nsClC III 1,747 0
155 M 30–74 Known COPD 1 8.5–9.9 5–5.9 sCC – nsClC III 741 1
156 M 75–91 Missing – spirometry 1 na na sClC IV 184 1
157 F 30–74 no COPD 1 8.5–9.9 5–5.9 sClC IV 398 1
158 M 30–74 no COPD 0 10–15 5–5.9 sClC IV 449 1
159 M 30–74 no COPD 0 10–15 3–4.9 ad-nsClC II 1,437 1
160 F 30–74 no COPD 0 10–15 3–4.9 ad-nsClC IV 166 1
161 M 30–74 no COPD 1 8.5–9.9 3–4.9 ad-nsClC IV 141 1
162 M 30–74 no COPD 0 10–15 3–4.9 sCC – nsClC III 1,001 1
163 F 30–74 Missing – spirometry 1 10–15 5–5.9 sClC IV 181 1
164 F 75–91 Known COPD 1 10–15 5–5.9 ad-nsClC II 335 1
165 F 30–74 Missing – spirometry 0 na na sCC – nsClC IV 236 1
166 F 75–91 Known COPD 1 8.5–9.9 5–5.9 Other – nsClC IV 68 1
167 M 30–74 Known COPD 1 8.5–9.9 6–10 ad-nsClC IV 9 1
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ID Sex Age-group,  
years




Cancer Stage Time D
168 M 30–74 Known COPD 1 4–8.4 5–5.9 sClC I 445 1
169 F 30–74 no COPD 0 na na sClC III 514 1
170 F 30–74 Known COPD 0 na na sClC IV 333 1
171 F 30–74 Known COPD 1 10–15 3–4.9 ad-nsClC II 243 1
172 F 30–74 Known COPD 1 4–8.4 5–5.9 sClC IV 244 1
173 F 30–74 no COPD 1 10–15 5–5.9 sCC – nsClC III 632 1
174 M 30–74 Missing – spirometry 1 na na ad-nsClC IV 57 1
Notes: Time represents survival time (days) from diagnosis of primary lung cancer; D represents a censoring variable (1 if dead, 0 if alive at the end of the study period); 
PaO2 and PaCO2 in kPa. Patients with missing data were categorized as “missing – spirometry”.
Abbreviations: ad-nsClC, adenocarcinoma non-small-cell lung cancer; emph, emphysema; F, female; M, male; na, not available; PaO2, partial arterial oxygen pressure; 
sCC, squamous cell carcinoma; sClC, small-cell lung cancer; PaCO2, partial arterial carbon dioxide pressure.
